A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting

Conclusions In the real-world treatment of patients with OAG or OHT, netarsudil consistently maintained IOP control when it replaced previous IOP-lowering therapies and provided additional IOP-lowering efficacy when added to other treatments.PMID:33733980 | DOI:10.1080/03007995.2021.1901222
Source: Current Medical Research and Opinion - Category: Research Authors: Source Type: research